search
Back to results

Study of Fluoxetine in Adults With Autistic Disorder

Primary Purpose

Autistic Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Fluoxetine
Sponsored by
Icahn School of Medicine at Mount Sinai
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Autistic Disorder focused on measuring Adult, Autism

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: Meets DSM-IV and ADI criteria for autistic disorder Patients must use effective contraception Negative pregnancy test Clinical Global Impression-Severity Scale for Autistic Disorder (CGI-AD) score of 4 Exclusion criteria: Pregnant or nursing Prior or concurrent history of mental disorders, including schizophrenia, schizoaffective disorder, organic mental disorders, or bipolar disorders Concurrent depression determined by DSM-IV diagnosis Serious suicidal risk Active seizure disorder within the past 2 years Clinically significant or unstable medical illness, including hematopoietic or cardiovascular disease Any organic or systemic disease Any geographical condition that would preclude study compliance Prior or concurrent gastrointestinal, liver, or kidney disease Any other concurrent condition that interferes with the absorption, distribution, metabolism, or excretion of drugs Prior or concurrent cerebrovascular disease or brain trauma Prior or concurrent clinically significant unstable endocrine disorder, such as hypo- or hyperthyroidism Prior or concurrent malignancy Clinically significant abnormalities on EKG, laboratory tests, or physical exam Requirement for ECT or any other psychotropic medication Inability to tolerate taper from psychoactive medication History of hypersensitivity or severe side effects associated with the use of fluoxitine or other serotonin reuptake inhibitors Treatment with any drug known to have a well-defined potential for toxicity to a major organ within the past 30 days Concurrent terfenadine (Seldane) or astemizole (Hismanal) Prior treatment with fluoxetine of 40 mg/day for 6 weeks Prior electroconvulsive therapy within the past 3 months Prior investigational drug use within the past 30 days Prior Monoamine oxidase inhibitor use within the past 14 days Prior long-acting phenothiazines within the past 6 weeks Prior psychotropic drugs within the past 7 days Prior fluoxetine within the past 6 weeks Requirement for any therapeutic intervention that would confound study evaluation

Sites / Locations

  • Mount Sinai School of Medicine

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
December 5, 2001
Last Updated
March 24, 2015
Sponsor
Icahn School of Medicine at Mount Sinai
search

1. Study Identification

Unique Protocol Identification Number
NCT00027404
Brief Title
Study of Fluoxetine in Adults With Autistic Disorder
Official Title
Fluoxetine vs Placebo in Adult Autistic Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
November 2002
Overall Recruitment Status
Completed
Study Start Date
September 2001 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
August 2005 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Icahn School of Medicine at Mount Sinai

4. Oversight

5. Study Description

Brief Summary
This is a study to determine the effect of fluoxetine in the treatment of adult autism and on functional ability and behavior associated with autism. Evidence suggests abnormal serotonin function in autism. Fluoxetine is a selective inhibitor of the serotonin transporter.
Detailed Description
Eligible patients will undergo comprehensive evaluation. Informants familiar with the patient will also provide information. Patients will be randomized to receive treatment or placebo. During the 12-week treatment there will be weekly monitoring for the first 4 weeks and biweekly monitoring for the next 8 weeks. The drug dosage will be increased each week as tolerated by the patient. Serum levels of fluoxetine and norfluoxetine will be documented at Week 12. Completion date provided represents the completion date of the grant per OOPD records

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autistic Disorder
Keywords
Adult, Autism

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
48 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Fluoxetine

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Meets DSM-IV and ADI criteria for autistic disorder Patients must use effective contraception Negative pregnancy test Clinical Global Impression-Severity Scale for Autistic Disorder (CGI-AD) score of 4 Exclusion criteria: Pregnant or nursing Prior or concurrent history of mental disorders, including schizophrenia, schizoaffective disorder, organic mental disorders, or bipolar disorders Concurrent depression determined by DSM-IV diagnosis Serious suicidal risk Active seizure disorder within the past 2 years Clinically significant or unstable medical illness, including hematopoietic or cardiovascular disease Any organic or systemic disease Any geographical condition that would preclude study compliance Prior or concurrent gastrointestinal, liver, or kidney disease Any other concurrent condition that interferes with the absorption, distribution, metabolism, or excretion of drugs Prior or concurrent cerebrovascular disease or brain trauma Prior or concurrent clinically significant unstable endocrine disorder, such as hypo- or hyperthyroidism Prior or concurrent malignancy Clinically significant abnormalities on EKG, laboratory tests, or physical exam Requirement for ECT or any other psychotropic medication Inability to tolerate taper from psychoactive medication History of hypersensitivity or severe side effects associated with the use of fluoxitine or other serotonin reuptake inhibitors Treatment with any drug known to have a well-defined potential for toxicity to a major organ within the past 30 days Concurrent terfenadine (Seldane) or astemizole (Hismanal) Prior treatment with fluoxetine of 40 mg/day for 6 weeks Prior electroconvulsive therapy within the past 3 months Prior investigational drug use within the past 30 days Prior Monoamine oxidase inhibitor use within the past 14 days Prior long-acting phenothiazines within the past 6 weeks Prior psychotropic drugs within the past 7 days Prior fluoxetine within the past 6 weeks Requirement for any therapeutic intervention that would confound study evaluation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric Hollander, MD
Organizational Affiliation
Mount Sinai School of Medicine New York, New York, United States
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Sinai School of Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study of Fluoxetine in Adults With Autistic Disorder

We'll reach out to this number within 24 hrs